Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study.

Objective: Heyndrickxia coagulans SANK70258, a representative probiotic, is known for alleviating inflammation caused by cedar pollen, improving the intestinal environment and bowel movements. A previous study on consuming H. coagulans SANK70258 together with galactooligosaccharides showed a trend toward improvement in skin scaliness scores and subjective assessments of skin roughness. However, the effect of H. coagulans SANK70258 alone on the skin remains unclear. Thus, we aimed to re-evaluate the effects of the intake of H. coagulans SANK70258 alone on skin conditions and the intestinal environment through a clinical trial.
Methods: This placebo-controlled, double-blind clinical trial involved 80 Japanese women aged 30 to 65 with perceived skin roughness. Participants were divided into placebo and test groups. Over eight weeks, the test group consumed H. coagulans SANK70258, and its effects on skin condition and intestinal health were examined.
Results: The probiotic group showed significant intestinal improvements, with reduced fecal phenol levels (p = 0.044) and pH (p = 0.022), as well as enhanced skin lightness (L* value) (p = 0.040) and liver function tests. Metabolic analyses revealed decreases in fecal Nε-(carboxymethyl)lysine and plasma hydroxyproline, suggesting skin health benefits. There were also significant improvements in skin scaliness (p = 0.015) and bowel movement frequency (p = 0.032) in subgroup analysis.
Conclusions: H. coagulans SANK70258 can improve skin health by improving the intestinal lining. This probiotic reduces the levels of intestinal putrefactive products and advanced glycation end-product levels in feces, suggesting that it may affect not only skin health but also systemic tissues such as the liver.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Naoyuki Togawa reports financial support was provided by Mitsubishi Chemical Corporation. Ryouichi Yamada, Yoshinori Aoki, Shouhei Suehiro, Noriyoshi Uchida reports financial support was provided by Mitsubishi Chemical Corporation. Akane Haseda, Hiroyo Kagami-Katsuyama, Naoyuki Honma, Jun Nishihira reports financial support was provided by Hokkaido Information University. Naoyuki Togawa reports a relationship with Mitsubishi Chemical Corporation that includes: employment. Ryouichi Yamada, Yoshinori Aoki, Shouhei Suehiro, Noriyoshi Uchida reports a relationship with Mitsubishi Chemical Corporation that includes: employment. Akane Haseda, Hiroyo Kagami-Katsuyama, Naoyuki Honma, Jun Nishihira reports a relationship with Hokkaido Information University that includes: employment. Naoyuki Togawa has patent Compositions for skin tone improvement pending to Mitsubishi chemical corporation. Ryouichi Yamada, Yoshinori Aoki, Shouhei Suehiro, Noriyoshi Uchida has patent Compositions for skin tone improvement pending to Mitsubishi chemical corporation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)